• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

侵袭性脑膜炎球菌病的全球流行病学。

Global epidemiology of invasive meningococcal disease.

机构信息

Department of Pediatrics and Child Health, Division of Women and Child Health, Aga Khan University, Stadium Road, Karachi, Pakistan.

出版信息

Popul Health Metr. 2013 Sep 10;11(1):17. doi: 10.1186/1478-7954-11-17.

DOI:10.1186/1478-7954-11-17
PMID:24016339
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3848799/
Abstract

Neisseria meningitidis is one of the leading causes of bacterial meningitis globally and can also cause sepsis, pneumonia, and other manifestations. In countries with high endemic rates, the disease burden places an immense strain on the public health system. The worldwide epidemiology of invasive meningococcal disease (IMD) varies markedly by region and over time. This review summarizes the burden of IMD in different countries and identifies the highest-incidence countries where routine preventive programs against Neisseria meningitidis would be most beneficial in providing protection. Available epidemiological data from the past 20 years in World Health Organization and European Centre for Disease Prevention and Control collections and published articles are included in this review, as well as direct communications with leading experts in the field. Countries were grouped into high-, moderate-, and low-incidence countries. The majority of countries in the high-incidence group are found in the African meningitis belt; many moderate-incidence countries are found in the European and African regions, and Australia, while low-incidence countries include many from Europe and the Americas. Priority countries for vaccine intervention are high- and moderate-incidence countries where vaccine-preventable serogroups predominate. Epidemiological data on burden of IMD are needed in countries where this is not known, particularly in South- East Asia and Eastern Mediterranean regions, so evidence-based decisions about the use of meningococcal vaccines can be made.

摘要

脑膜炎奈瑟菌是全球细菌性脑膜炎的主要病因之一,也可引起败血症、肺炎和其他表现。在地方性流行率较高的国家,这种疾病给公共卫生系统带来了巨大的负担。全球侵袭性脑膜炎球菌病(IMD)的流行病学在不同地区和不同时间有显著差异。本综述总结了不同国家 IMD 的负担,并确定了发病率最高的国家,在这些国家,针对脑膜炎奈瑟菌的常规预防规划将最有利于提供保护。本综述纳入了过去 20 年世界卫生组织和欧洲疾病预防控制中心收集的流行病学数据以及已发表的文章,以及与该领域主要专家的直接交流。根据发病率将国家分为高、中、低发病率国家。高发病率国家主要集中在非洲脑膜炎带;许多中发病率国家位于欧洲和非洲地区以及澳大利亚;低发病率国家包括许多来自欧洲和美洲的国家。疫苗干预的优先国家是高发病率和中发病率国家,这些国家以疫苗可预防的血清群为主。在那些尚不清楚 IMD 负担的国家,需要有关于 IMD 负担的流行病学数据,特别是在东南亚和东地中海地区,以便能够做出基于证据的脑膜炎球菌疫苗使用决策。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ed6/3848799/53cb68e737a3/1478-7954-11-17-2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ed6/3848799/7badd7346db8/1478-7954-11-17-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ed6/3848799/53cb68e737a3/1478-7954-11-17-2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ed6/3848799/7badd7346db8/1478-7954-11-17-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ed6/3848799/53cb68e737a3/1478-7954-11-17-2.jpg

相似文献

1
Global epidemiology of invasive meningococcal disease.侵袭性脑膜炎球菌病的全球流行病学。
Popul Health Metr. 2013 Sep 10;11(1):17. doi: 10.1186/1478-7954-11-17.
2
The everchanging epidemiology of meningococcal disease worldwide and the potential for prevention through vaccination.全球脑膜炎奈瑟菌病的不断变化的流行病学和通过疫苗接种进行预防的可能性。
J Infect. 2020 Oct;81(4):483-498. doi: 10.1016/j.jinf.2020.05.079. Epub 2020 Jun 3.
3
Epidemiology of invasive meningococcal disease worldwide from 2010-2019: a literature review.全球 2010-2019 年侵袭性脑膜炎奈瑟菌病的流行病学:文献综述。
Epidemiol Infect. 2023 Mar 6;151:e57. doi: 10.1017/S0950268823000328.
4
Meningococcal serogroup Y disease in Europe: Continuation of high importance in some European regions in 2013.欧洲的Y群脑膜炎球菌病:2013年在欧洲一些地区仍具有高度重要性。
Hum Vaccin Immunother. 2015;11(9):2281-6. doi: 10.1080/21645515.2015.1051276.
5
Invasive meningococcal disease in older adults in North America and Europe: is this the time for action? A review of the literature.北美和欧洲老年人侵袭性脑膜炎球菌病:现在是采取行动的时候了吗?文献综述
BMC Public Health. 2022 Feb 23;22(1):380. doi: 10.1186/s12889-022-12795-9.
6
Global epidemiology of meningococcal disease.脑膜炎球菌病的全球流行病学
Vaccine. 2009 Jun 24;27 Suppl 2:B51-63. doi: 10.1016/j.vaccine.2009.04.063. Epub 2009 May 27.
7
Invasive meningococcal disease in South-Eastern European countries: Do we need to revise vaccination strategies?中东欧国家侵袭性脑膜炎球菌病:我们是否需要修订疫苗接种策略?
Hum Vaccin Immunother. 2024 Dec 31;20(1):2301186. doi: 10.1080/21645515.2023.2301186. Epub 2024 Jan 4.
8
The Global Evolution of Meningococcal Epidemiology Following the Introduction of Meningococcal Vaccines.引入脑膜炎球菌疫苗后脑膜炎球菌流行病学的全球演变
J Adolesc Health. 2016 Aug;59(2 Suppl):S3-S11. doi: 10.1016/j.jadohealth.2016.04.012.
9
Prevention and control of meningococcal disease: Updates from the Global Meningococcal Initiative in Eastern Europe.预防和控制脑膜炎球菌病:东欧全球脑膜炎球菌倡议的最新进展。
J Infect. 2019 Dec;79(6):528-541. doi: 10.1016/j.jinf.2019.10.018. Epub 2019 Nov 1.
10
The epidemiology of invasive meningococcal disease in EU/EEA countries, 2004-2014.2004 - 2014年欧盟/欧洲经济区国家侵袭性脑膜炎球菌病的流行病学
Vaccine. 2017 Apr 11;35(16):2034-2041. doi: 10.1016/j.vaccine.2017.03.007. Epub 2017 Mar 14.

引用本文的文献

1
Prevalence and Risk of Meningococcal Disease or Carriage During Mass Gatherings and Associated Travel: Systematic Review and Meta-Analysis.群体性活动及相关旅行期间脑膜炎球菌病或带菌状态的患病率和风险:系统评价与荟萃分析
Trop Med Infect Dis. 2025 Jul 25;10(8):207. doi: 10.3390/tropicalmed10080207.
2
Epidemiological characteristics of invasive meningococcal disease and carriage prevalence of in the Xinjiang Uygur Autonomous Region, China, 2004-2023: a retrospective study.2004 - 2023年中国新疆维吾尔自治区侵袭性脑膜炎球菌病的流行病学特征及携带率:一项回顾性研究
PeerJ. 2025 Jul 29;13:e19772. doi: 10.7717/peerj.19772. eCollection 2025.
3

本文引用的文献

1
Emergence of serogroup X meningococcal disease in Africa: need for a vaccine.非洲出现 X 群脑膜炎球菌病:需要疫苗。
Vaccine. 2013 Jun 12;31(27):2852-61. doi: 10.1016/j.vaccine.2013.04.036. Epub 2013 Apr 24.
2
Meningococcal vaccines: WHO position paper, November 2011.脑膜炎球菌疫苗:世界卫生组织立场文件,2011年11月
Wkly Epidemiol Rec. 2011 Nov 18;86(47):521-39.
3
Neisseria meningitidis: biology, microbiology, and epidemiology.脑膜炎奈瑟菌:生物学、微生物学及流行病学
Sudden Cardiac Death in Pregnant Women-Literature Review and Autopsy Findings.
孕妇心源性猝死——文献综述与尸检结果
Diagnostics (Basel). 2025 Apr 27;15(9):1108. doi: 10.3390/diagnostics15091108.
4
Public health impact and cost-effectiveness of introducing MenACWY vaccination strategies in Germany.在德国引入A群脑膜炎球菌结合疫苗(MenACWY)接种策略的公共卫生影响和成本效益
BMC Public Health. 2025 May 5;25(1):1653. doi: 10.1186/s12889-025-21491-3.
5
Meningococcal C Disease Outbreak Caused by Multidrug-Resistant Neisseria meningitidis, Fiji.斐济由多重耐药性脑膜炎奈瑟菌引起的C群脑膜炎球菌病暴发
Emerg Infect Dis. 2025 Jan;31(1):32-40. doi: 10.3201/eid3101.240476.
6
Characterization of a Hypothetical Protein (PBJ89160.1) from Exhibits a New Insight on Nutritional Virulence and Molecular Docking to Uncover a Therapeutic Target.来自[具体来源未提及]的一种假设蛋白(PBJ89160.1)的表征为营养毒力和分子对接以揭示治疗靶点提供了新见解。
Evol Bioinform Online. 2024 Nov 11;20:11769343241298307. doi: 10.1177/11769343241298307. eCollection 2024.
7
Quadrivalent Conjugate Vaccine and Invasive Meningococcal Disease in US Adolescents and Young Adults.四价结合疫苗与美国青少年和青年人群侵袭性脑膜炎球菌病。
JAMA Netw Open. 2024 Nov 4;7(11):e2443551. doi: 10.1001/jamanetworkopen.2024.43551.
8
Guidelines for the vaccination of HIV-infected adolescents and adults in South Africa.南非艾滋病毒感染青少年和成人的疫苗接种指南。
South Afr J HIV Med. 2018 May 23;19(1):839. doi: 10.4102/sajhivmed.v19i1.839. eCollection 2018.
9
Factor H binding protein (FHbp): An evaluation of genotypic diversity across serogroups.因子 H 结合蛋白(FHbp):对各血清群的基因多样性评估。
Hum Vaccin Immunother. 2024 Dec 31;20(1):2409502. doi: 10.1080/21645515.2024.2409502. Epub 2024 Oct 10.
10
Junctions at the crossroads: the impact of mechanical cues on endothelial cell-cell junction conformations and vascular permeability.交叉口的连接点:机械线索对内皮细胞-细胞连接构象和血管通透性的影响。
Am J Physiol Cell Physiol. 2024 Oct 1;327(4):C1073-C1086. doi: 10.1152/ajpcell.00605.2023. Epub 2024 Aug 12.
Methods Mol Biol. 2012;799:1-20. doi: 10.1007/978-1-61779-346-2_1.
4
Product development partnerships hit their stride: lessons from developing a meningitis vaccine for Africa.产品研发合作步入正轨:从开发针对非洲的脑膜炎疫苗中吸取的经验教训。
Health Aff (Millwood). 2011 Jun;30(6):1058-64. doi: 10.1377/hlthaff.2011.0295.
5
Meningococcal disease in Asia: an under-recognized public health burden.亚洲的脑膜炎球菌病:一个被低估的公共卫生负担。
Epidemiol Infect. 2011 Jul;139(7):967-85. doi: 10.1017/S0950268811000574. Epub 2011 Apr 15.
6
The Global Meningococcal Initiative: recommendations for reducing the global burden of meningococcal disease.全球流脑倡议:降低全球流脑疾病负担的建议。
Vaccine. 2011 Apr 18;29(18):3363-71. doi: 10.1016/j.vaccine.2011.02.058. Epub 2011 Mar 3.
7
Annual report of the Australian Meningococcal Surveillance Programme, 2009.《2009年澳大利亚脑膜炎球菌监测计划年度报告》
Commun Dis Intell Q Rep. 2010 Sep;34(3):291-302.
8
The epidemiology of meningococcal disease in India.印度脑膜炎奈瑟菌病的流行病学。
Trop Med Int Health. 2010 Dec;15(12):1421-35. doi: 10.1111/j.1365-3156.2010.02660.x. Epub 2010 Nov 5.
9
Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis.全球和地区细菌性脑膜炎致残后遗症风险:系统评价和荟萃分析。
Lancet Infect Dis. 2010 May;10(5):317-28. doi: 10.1016/S1473-3099(10)70048-7.
10
Epidemiology of meningococcal disease in Latin America: current situation and opportunities for prevention.拉丁美洲脑膜炎球菌病的流行病学:现状与预防机遇
Neurol Res. 2010 Apr;32(3):263-71. doi: 10.1179/016164110X12644252260754.